HIV vac­cine re­mains Holy Grail as Sanofi/GSK reg­i­men dis­ap­points in large study

An HIV vac­cine reg­i­men com­pris­ing ex­per­i­men­tal com­po­nents sup­plied by Sanofi and Glax­o­SmithK­line has been de­clared in­ef­fec­tive, un­der­scor­ing the dif­fi­cul­ty of this un­der­tak­ing and rais­ing the stakes for a mo­sa­ic vac­cine be­ing test­ed by a J&J-led coali­tion.

The Na­tion­al In­sti­tute of Al­ler­gy and In­fec­tious Dis­eases has stopped ad­min­is­ter­ing vac­cines in the HVTN 702 tri­al af­ter an in­ter­im re­view con­clud­ed that it didn’t pre­vent HIV. The Phase IIb/III tri­al en­rolled 5,407 HIV-neg­a­tive vol­un­teers in South Africa.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER